Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia

Proprotein convertase-subtilisin/kexin type 9 (PCSK9) monoclonal antibody is a new therapy to reduce low-density lipoprotein cholesterol (LDL-C) level in patients with familial hypercholesterolemia (FH). This pooled analysis aimed to estimate the efficacy and safety of PCSK9 antibody therapy in FH....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Li, Bin, Hao, Pan-Pan, Zhang, Yong, Yin, Rui-Hong, Kong, Qing-Zan, Cai, Xiao-Jun, Zhao, Zhuo, Qi, Jian-Ni, Li, Ying, Xiao, Jie, Wang, Fu, Yi, Wei, Ji, Xiao-Ping, Su, Guo-Hai
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Clinical Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444755/
https://ncbi.nlm.nih.gov/pubmed/27458166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10762
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi